Calithera Biosciences (CALA) Raised to “Buy” at ValuEngine

Share on StockTwits

Calithera Biosciences (NASDAQ:CALA) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Friday.

Shares of CALA stock traded up $0.01 on Friday, hitting $6.43. The stock had a trading volume of 400,800 shares, compared to its average volume of 164,533. The company has a market capitalization of $254.78 million, a P/E ratio of -4.32 and a beta of 2.28. Calithera Biosciences has a one year low of $3.55 and a one year high of $7.65.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.03). Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 39.19%. On average, analysts predict that Calithera Biosciences will post -1.82 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in CALA. Dimensional Fund Advisors LP raised its holdings in shares of Calithera Biosciences by 25.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,244,046 shares of the biotechnology company’s stock valued at $4,988,000 after acquiring an additional 256,222 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Calithera Biosciences by 84.5% in the third quarter. JPMorgan Chase & Co. now owns 225,780 shares of the biotechnology company’s stock worth $1,186,000 after purchasing an additional 103,434 shares in the last quarter. Geode Capital Management LLC raised its holdings in Calithera Biosciences by 26.6% in the fourth quarter. Geode Capital Management LLC now owns 348,667 shares of the biotechnology company’s stock worth $1,398,000 after purchasing an additional 73,250 shares in the last quarter. Vanguard Group Inc raised its holdings in Calithera Biosciences by 5.4% in the third quarter. Vanguard Group Inc now owns 1,291,646 shares of the biotechnology company’s stock worth $6,781,000 after purchasing an additional 65,934 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Calithera Biosciences by 5.4% in the third quarter. Vanguard Group Inc. now owns 1,291,646 shares of the biotechnology company’s stock worth $6,781,000 after purchasing an additional 65,934 shares in the last quarter. Hedge funds and other institutional investors own 57.05% of the company’s stock.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

See Also: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

iShares Russell 1000 ETF  Holdings Cut by Freestone Capital Holdings LLC
iShares Russell 1000 ETF Holdings Cut by Freestone Capital Holdings LLC
Checchi Capital Advisers LLC Buys Shares of 1,026 IDEXX Laboratories, Inc.
Checchi Capital Advisers LLC Buys Shares of 1,026 IDEXX Laboratories, Inc.
Catalyst Capital Advisors LLC Acquires Shares of 5,400 CHIMERA INVT CO/SH NEW
Catalyst Capital Advisors LLC Acquires Shares of 5,400 CHIMERA INVT CO/SH NEW
Godaddy Inc  Shares Sold by Catalyst Capital Advisors LLC
Godaddy Inc Shares Sold by Catalyst Capital Advisors LLC
Brokerages Set Scorpio Bulkers Inc  Price Target at $9.33
Brokerages Set Scorpio Bulkers Inc Price Target at $9.33
Argus Downgrades Expedia Group  to Hold
Argus Downgrades Expedia Group to Hold


© 2006-2019 Ticker Report